Alder Biopharmaceuticals Inc. and Eli Lilly and Co. stand as the only developers of calcitonin gene-related peptide (CGRP) blockers that have generated human efficacy data in migraine patients, but Amgen Inc. and Teva Pharmaceuticals Ltd. are courting similar phase II success in the clinic.